featured
Effect of an RNA Interference Drug on the Synthesis of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Concentration of Serum LDL Cholesterol in Healthy Volunteers: A Randomised, Single-Blind, Placebo-Controlled, Phase 1 Trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet